Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Long-Term Debt Repayments (2024 - 2025)

Puma Biotechnology's Long-Term Debt Repayments history spans 2 years, with the latest figure at $11.1 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed 0.0% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $44.4 million, up 33.33%, while the annual FY2025 figure was $44.4 million, 33.33% up from the prior year.
  • Long-Term Debt Repayments reached $11.1 million in Q4 2025 per PBYI's latest filing, roughly flat from $11.1 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $11.1 million in Q2 2024 to a low of $11.1 million in Q2 2024.